Latest stories on SNDX
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Business Insider50 · neutralearnings
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
GlobeNewswire50 · neutralgeneral
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
GlobeNewswire63 · neutralproduct/pr
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
StockTitan64 · neutralproduct/pr
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
PR Newswire34 · bearishgeneral
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
Barron's22 · bearishearnings
Syndax drops after axatilimab misses MAXPIRe IPF endpoint, while cGVHD program stays on track
MarketChameleon34 · bearishearnings
Stifel maintains Syndax stock rating after trial failure
Investing.com Analyst Ratings42 · neutralanalyst
Syndax valuation unchanged after trial miss, says H.C. Wainwright
The Fly42 · neutralanalyst
Syndax selloff brings attractive entry point, says Citi
The Fly64 · neutralanalyst
Why is Syndax Pharmaceuticals stock sliding today?
Investing.com Markets38 · neutralgeneral
Syndax halts axatilimab IPF plans after MAXPIRe misses FVC decline endpoint
October 13, 2026
MarketChameleon34 · bearishearnings
Syndax price target lowered to $23 from $26 at BofA
The Fly34 · bearishanalyst
SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?
Stocktwits News22 · bearishearnings
Syndax plummets as IPF asset axatilimab fails in phase 2 trial
Seeking Alpha14 · bearishearnings
Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint
The Fly22 · bearishearnings
Syndax sinks 15% to $14 after idiopathic pulmonary fibrosis miss
The Fly22 · bearishearnings
Syndax to end development of axatilimab in idiopathic pulmonary fibrosis
The Fly34 · bearishproduct/pr
Syndax says idiopathic pulmonary fibrosis study did not meet endpoint
The Fly22 · bearishproduct/pr
Syndax Pharmaceuticals stock tumbles on failed IPF trial
Investing.com Markets14 · bearishgeneral
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
StockTitan58 · neutralproduct/pr
H.C. Wainwright reiterates Buy on Syndax stock, $38 target
Investing.com Analyst Ratings61 · neutralanalyst
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
H.C. Wainwright reiterates Syndax stock Buy rating at $38 target
Investing.com Analyst Ratings61 · neutralanalyst